Aikomi

Name

Aikomi

Legal name

株式会社Aikomi

Website

https://aikomi.co.jp

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Aikomi is a Japan-based digital therapeutics company that uses AI and IoT to deliver person-centered dementia care through a personalized memory-based platform connecting patients, families, and care professionals.

Ownership category

akta.pro rank

Product category

Digital Therapeutics for Dementia Care

NAICS

Services for the Elderly and Persons with Disabilities (62412)

SIC

Services-Social Services (8300)

akta.pro primary industry

Dementia Companion & Engagement Care (HSABAEAA)

akta.pro secondary industries

Cognitive Stimulation & Reminiscence Therapy (Non-Clinical) (HSABAEAH), Remote Therapeutic Monitoring (RTM) & Digital Rehabilitation Platforms (HLALABAK), Technology Assistance & Digital Support for Seniors (HSABAAAH)

Keywords

• Digital therapeutics
• Dementia care platform
• AI memory therapy
• Person-centered care
• Healthcare IoT platform

Headquarters

HQ city

Yokohama

HQ country

Japan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. Platform Services: Digital therapy platform providing personalized dementia care content and communication tools for the Dementia Care Triad. Remote usage capability allows maintenance of connections when in-person contact is limited. Psychological support system for isolated family members also planned.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

Aikomi offers a digital therapy platform that uses AI and IoT to help people with dementia experience fragments of their remaining memories through visual, auditory, olfactory, and tactile modalities. The platform is designed to facilitate communication and connection within the "Dementia Care Triad" of patients, families, and healthcare/welfare professionals, enabling remote care delivery and supporting person-centered care.

Product overview

Aikomi offers a single unified digital therapy platform (the Aikomi Platform) designed to deliver Person-Centered Care for people with dementia. The platform uses AI to provide personalized programs based on each patient's life history, memories, and preferences, enabling them to experience memory fragments through visual, auditory, and sensory means. These shared experiences facilitate communication among the Dementia Care Triad (patients, families, and care workers), improving quality of life and reducing behavioral and psychological symptoms of dementia.

Differentiator

Problem solved

Functional benefit

Products and services

• Aikomi Platform A digital therapy platform that uses AI and IoT to enable people with dementia to see, hear, smell, and touch fragments of their remaining memories through personalized content based on individual life history, abilities, and preferences. The platform facilitates communication among the Dementia Care Triad (patients, families, and healthcare/welfare professionals), supports remote care delivery when in-person contact is limited, and is delivered via tablet-based applications to care facilities, hospitals, and families.

Quantifiable outcome

• Preliminary efficacy study with Australian university showed potential to promote spontaneity in people with dementia and improve family relationships

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Partnerships

Five partnerships are on record, tiered minor and core.

• Asahi Beverages (アサヒ飲料株式会社)minorStrategic or Co-development Partner · 1 May 2026Research collaboration using 'Calpis' beverage to prevent social isolation among elderly. Presented findings at 27th Japan Dementia Care Society conference. Relationship model for social connection through beverage as medium.
• Australian University (Australian university)minorStrategic or Co-development Partner · 1 January 2021Conducted preliminary efficacy verification of Aikomi platform. Study suggested personalized programs may promote spontaneity in people with dementia and improve family relationships.
• Sompo Japan (損害保険ジャパン株式会社)coreStrategic or Co-development Partner · 1 August 2020Three-party collaboration with Sumitomo Pharma and Sompo Japan initiated August 2020, focused on dementia care digital therapy ecosystem development.
• Sumitomo Pharma (住友ファーマ株式会社)coreStrategic or Co-development Partner · 1 February 2019Joint research collaboration began February 2019, followed by investment in June 2020. Three-party collaboration established with Sompo Japan in August 2020. Continued partnership for dementia care digital therapy development and validation.
• FUNDINNOminorGTM or Marketing PartnerEquity crowdfunding platform used for fundraising. Achieved 9,486万円 (941% of target) in December 2024 campaign.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Altoida: Altoida develops digital biomarkers and AI-driven cognitive assessment tools for early dementia detection and monitoring, overlapping directly with Aikomi's AI-based personalized dementia care platform. Both target the dementia patient–family–clinician engagement loop using smartphone/tablet-based digital tools.
• Neurotrack: Neurotrack offers a digital cognitive health platform for memory assessment and dementia risk reduction, with content-driven brain training similar in spirit to Aikomi's reminiscence-based engagement therapy. Both sell to consumers, providers, and payers to delay or manage cognitive decline.
• Cogstate: Cogstate provides computerized cognitive assessment and training tools used widely in clinical trials and healthcare for dementia and other neurological conditions. It is comparable to Aikomi in delivering digital, repeated cognitive measurement and therapy, but operates more upstream in clinical research and pharma.
• Posit Science (BrainHQ): Posit Science's BrainHQ offers computerized cognitive training exercises marketed for healthy aging and dementia risk reduction, overlapping with Aikomi's cognitive stimulation via digital platform. Both are subscription-style consumer/clinical cognitive intervention products targeting older adults.
• Constant Therapy: Constant Therapy delivers AI-personalized digital speech, language, and cognitive therapy exercises on tablet/app to patients with neurological conditions including dementia and stroke. Like Aikomi, it emphasizes per-patient personalization and remote delivery to caregivers and clinicians.
• MindMaze: MindMaze builds digital therapeutics for neurological recovery and cognitive assessment using AI, VR, and multimodal interfaces. The architecture (AI personalization, multi-sensory engagement, clinical-grade delivery) is closely analogous to Aikomi's reminiscence-based platform, though MindMaze targets stroke and TBI more heavily.
• Dthera Sciences: Dthera Sciences developed a digital therapeutic for Alzheimer's disease and dementia aimed at reducing agitation and improving quality of life through personalized content. Despite commercial setbacks, it is one of the closest historical analogues to Aikomi's AI-personalized reminiscence therapy approach for dementia patients.
• Rendever: Rendever provides VR-based reminiscence therapy for seniors living with dementia and social isolation in senior living communities. Both companies use immersive, personalized, memory-based content to engage dementia patients and connect them with families and caregivers.
• Memrica: Memrica offers a memory aid app that uses personal life history to support recall and daily living for people with early-stage dementia. It targets the same dementia patient + family + caregiver triangle as Aikomi, with content personalized to individual biography.

Regional players

• Silverwood (Sompo Care Link subsidiary, Japan): Silverwood builds senior housing and care service platforms in Japan, including dementia-focused group homes and tech-enabled care. It is comparable to Aikomi as a Japan-based player addressing dementia care delivery, and is a potential partner/customer given its existing Sompo Japan ecosystem overlap.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/aikomi_dementia

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aikomi